Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib

Cancer Letters

Volumn 352, Issue 2, 2014, Pages 245-252

  Mao, Kai ^a   Zhang, Jianlong ^a   He, Chuanchao ^a   Xu, Kang ^a   Liu, Jieqiong ^a   Sun, Jian ^a   Wu, Gang ^b   Tan, Cui ^a   Zeng, Yunjie ^a   Wang, Jie ^a   Xiao, Zhiyu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Apoptosis; Hepatitis B virus; Hepatocellular carcinoma; MiR 193b; Myeloid cell leukemia 1; Sorafenib

Indexed keywords

CASPASE 3; MICRORNA; MICRORNA 193B; MYELOID LEUKEMIA FACTOR 1; SORAFENIB; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN TARGETING; WESTERN BLOTTING;

HEPATITIS B VIRUS;

APOPTOSIS; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; MIR-193B; MYELOID CELL LEUKEMIA-1; SORAFENIB;

3' UNTRANSLATED REGIONS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENES, REPORTER; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MICRORNAS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; TIME FACTORS; TRANSFECTION;

EID: 84906058663     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.004     Document Type: Article

References (44)

1. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. The Lancet 2012, 379:1245-1255.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer J. Clinicians 2011, 61:69-90.
3. El-Serag H.B. Hepatocellular Carcinoma. N. Engl. J. Med. 2011, 365:1118-1127.
4. Santoro A., Rimassa L. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Exp. Rev. Anticancer Ther. 2009, 9:739-745.
5. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
6. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
7. Adnane L., Trail P.A., Taylor I., Wilhelm S.M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006, 407:597-612.
8. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C. Sorafenib blocks the RAF/MEK/ERK pathway inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 15:11851-11858.
9. Carlomagno F., Anaganti S., Guida T., Salvatore G., Troncone G., Wilhelm S.M., Santoro M. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 2006, 98:326-334.
10. Miyamoto Y., Hosotani R., Wada M., Lee J.U., Koshiba T., Fujimoto K., Tsuji S., Nakajima S., Doi R., Kato M., Shimada Y., Imamura M. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 1999, 56:73-82.
11. Chung T.K., Cheung T.H., Lo W.K., Yim S.F., Yu M.Y., Krajewski S., Reed J.C., Wong Y.F. Expression of apoptotic regulators and their significance in cervical cancer. Cancer Lett. 2002, 180:63-68.
12. Cho-Vega J.H., Rassidakis G.Z., Admirand J.H., Oyarzo M., Ramalingam P., Paraguya A., McDonnell T.J., Amin H.M., Medeiros L.J. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum. Pathol. 2004, 35:1095-1100.
13. Khoury J.D., Medeiros L.J., Rassidakis G.Z., McDonnell T.J., Abruzzo L.V., Lai R. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J. Pathol. 2003, 199:90-97.
14. Sieghart W., Losert D., Strommer S., Cejka D., Schmid K., Rasoul-Rockenschaub S., Bodingbauer M., Crevenna R., Monia B.P., Peck-Radosavljevic M., Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol. 2006, 44:151-157.
15. Fleischer B., Schulze-Bergkamen H., Schuchmann M., Weber A., Biesterfeld S., Muller M., Krammer P.H., Galle P.R. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int. J. Oncol. 2006, 28:25-32.
16. Thomas L.W., Lam C., Edwards S.W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010, 584:2981-2989.
17. Rahmani M., Davis E.M., Bauer C., Dent P., Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 2005, 280:35217-35227.
18. Yu C., Bruzek L.M., Meng X.W., Gores G.J., Carter C.A., Kaufmann S.H., Adjei A.A. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005, 24:6861-6869.
19. Crawford M., Batte K., Yu L., Wu X., Nuovo G.J., Marsh C.B., Otterson G.A., Nana-Sinkam S.P. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem. Biophys. Res. Commun. 2009, 388:483-489.
20. Garzon R., Heaphy C.E., Havelange V., Fabbri M., Volinia S., Tsao T., Zanesi N., Kornblau S.M., Marcucci G., Calin G.A., Andreeff M., Croce C.M. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
21. Mott J.L., Kobayashi S., Bronk S.F., Gores G.J. Mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26:6133-6140.
22. Wang H.J., Ruan H.J., He X.J., Ma Y.Y., Jiang X.T., Xia Y.J., Ye Z.Y., Tao H.Q. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur. J. Cancer 2010, 46:2295-2303.
23. Xu C., Liu S., Fu H., Li S., Tie Y., Zhu J., Xing R., Jin Y., Sun Z., Zheng X. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur. J. Cancer 2010, 46:2828-2836.
24. Su H., Yang J.R., Xu T., Huang J., Xu L., Yuan Y., Zhuang S.M. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009, 69:1135-1142.
25. Xiong Y., Fang J.H., Yun J.P., Yang J., Zhang Y., Jia W.H., Zhuang S.M. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
26. McGlynn K.A., Tsao L., Hsing A.W., Devesa S.S., Fraumeni J.F. International trends and patterns of primary liver cancer. Int. J. Cancer 2001, 94:290-296.
27. L. Bolondi, W. Caspary, J. Bennouna, Clinical benefit of sorafenib in Hepatitis C patients with hepatocellular carcinoma (HCC): Subgroup analysis of the SHARP tria., in: Proc. Am. Soc. Clin. Oncol. Gastrointestinal Cancer Symp, [abstract # 129], 2008.
28. Braconi C., Valeri N., Gasparini P., Huang N., Taccioli C., Nuovo G., Suzuki T., Croce C.M., Patel T. Hepatitis C virus proteins modulate MicroRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res. 2010, 16:957-966.
29. Cheng A.L., Guan Z., Chen Z., Tsao C.J., Qin S., Kim J.S., Yang T.S., Tak W.Y., Pan H., Yu S., Xu J., Fang F., Zou J., Lentini G., Voliotis D., Kang Y.K. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur. J. Cancer 2012, 48:1452-1465.
30. He C., Xu J., Zhang J., Xie D., Ye H., Xiao Z., Cai M., Xu K., Zeng Y., Li H., Wang J. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum. Pathol. 2012, 43:1425-1435.
31. Dolled-Filhart M., Camp R.L., Rimm D.L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 2004, 10(21):7252-7259.
32. J.F. Fecteau, I.S. Bharati, M. O'Hayre, T.M. Handel, T.J. Kipps, D. Messmer, Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1), Mol. Med. 10 (2012) 19-28 (February).
33. Chen J., Zhang X., Lentz C., Abi-Daoud M., Pare G.C., Yang X., Feilotter H.E., Tron V.A. MiR-193b regulates Mcl-1 in melanoma. Am. J. Pathol. 2011, 179:2162-2168.
34. Ramakrishnan V., Timm M., Haug J.L., Kimlinger T.K., Wellik L.E., Witzig T.E., Rajkumar S.V., Adjei A.A., Kumar S. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010, 29:1190-1202.
35. Chang W.T., Kao W.Y., Chau G.Y., Su C.W., Lei H.J., Wu J.C., Hsia C.Y., Lui W.Y., King K.L., Lee S.D. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection?. Surgery 2012, 152:809-820.
36. Zhang Z.Z., Liu X., Wang D.Q., Teng M.K., Niu L.W., Huang A.L., Liang Z. Hepatitis B virus and hepatocellular carcinoma at the miRNA level. World J. Gastroenterol. 2011, 17:3353-3358.
37. Chen J., Feilotter H.E., Paré G.C., Zhang X., Pemberton J.G.W., Garady C., Lai D., Yang X., Tron V.A. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol. 2010, 176:2520-2529.
38. Li X.F., Yan P.J., Shao Z.M. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009, 28:3937-3948.
39. Kew M.C. Hepatitis B virus x protein in the pathogenesis of Hepatitis B virus-induced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2011, 26(Suppl. 1):144-152.
40. Lee J.O., Kwun H.J., Jung J.K., Choi K.H., Min D.S., Jang K.L. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 2005, 24:6617-6625.
41. Liu J., Lian Z., Han S., Waye M.M., Wang H., Wu M.C., Wu K., Ding J., Arbuthnot P., Kew M., Fan D., Feitelson M.A. Downregulation of E-cadherin by Hepatitis B virus X antigen in hepatocellular carcinoma. Oncogene 2006, 25:1008-1017.
42. Jung J.K., Park S.H., Jang K.L. Hepatitis B virus X protein overcomes the growth-inhibitory potential of retinoic acid by downregulating retinoic acid receptor-beta2 expression via DNA methylation. J. Gen. Virol. 2010, 91:493-500.
43. Zhang T., Zhang J., Cui M., Liu F., You X., Du Y., Gao Y., Zhang S., Lu Z., Ye L., Zhang X. Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. Neoplasia 2013, 15:1282-1291.
44. Rauhala H.E., Jalava S.E., Isotalo J., Bracken H., Lehmusvaara S., Tammela T.L., Oja H., Visakorpi T. MiR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int. J. Cancer 2010, 127:1363-1372.